hC Bioscience, Inc.
10:15 AM - 10:30 AM (EST), Tuesday, February 7, 2023 ・ Music Box
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically-defined conditions which account for 10-15% of all human disease.
As the building blocks and machinery of life, proteins are made from long chains of specific amino acids coded by DNA. Errors in the DNA code often lead to errors in proteins, resulting in dysfunction and many genetically-defined diseases. Our team is addressing these diseases directly by creating first-in-class tRNA-based therapies that correct the proteins caused by many forms of DNA coding errors.
As the building blocks and machinery of life, proteins are made from long chains of specific amino acids coded by DNA. Errors in the DNA code often lead to errors in proteins, resulting in dysfunction and many genetically-defined diseases. Our team is addressing these diseases directly by creating first-in-class tRNA-based therapies that correct the proteins caused by many forms of DNA coding errors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Non-Disclosed
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
